Introduction
Interleukin-6 (IL-6) is a proinflammatory cytokine that was first identified as a B-cell stimulatory factor (1) . The mature protein consists of 184 amino acids that form a fourhelix bundle with the up-up-down-down topology common to most cytokines (2) . On elucidation of its cDNA sequence (1) , it became apparent that IL-6 was identical to hepatocytestimulating factor (3), hybridoma/plasmacytoma growth factor (4), interferon-β2 (5) , and a 26-kDa protein with unknown function (6) . Although this early observation provided initial clues to the pleiotropic nature of IL-6, it is now known that IL-6 has many functions in the regulation and coordination of the immune system, metabolism, and nervous system (7, 8) . Not only is it involved in many autoimmune diseases, it also (16) . Furthermore, cells that do not express IL-6R and that are therefore not directly responsive to IL-6 can be stimulated by the complex of IL-6 and sIL-6R (9) . This process, which has been termed IL-6 trans-signaling, dramatically increases the spectrum of IL-6 target cells (13) . It has been shown that IL-6 trans-signaling through sIL-6R is mainly proinflammatory, whereas IL-6 classic signaling through mIL-6R is associated with protective effects against infections and regenerative activities (8) . IL-6 trans-signaling can be efficiently blocked by the soluble gp130Fc protein, which consists of the entire extracellular portion of gp130 dimerized by the Fc portion of a human immunoglobulin G1 (IgG1) antibody (9, 11) . Blockade of IL-6 trans-signaling by the soluble gp130Fc protein leaves all classic IL-6 signaling through mIL-6R intact (11) (Fig. 1) . As a result, it has been proposed that selective inhibition of IL-6 trans-signaling might be a more prudent mode of IL-6 inhibition because its protective and regenerative activities are not compromised by this strategy (17, 18) .
Intracellular signaling
The dimerization of gp130 leads to activation of Janus kinase (JAK) tyrosine kinases (19) , which are constitutively bound to the intracellular portion of the gp130 protein (20) (Fig. 1 ). There are five tyrosine residues within the cytoplasmic tail of gp130 that are phosphorylated primarily by JAK1 (20) . The membrane proximal tyrosine residue acts as a docking site for SHP2, which is an adapter protein and a tyrosine phosphatase, leading to the activation of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling (19, 21) . The membrane proximal tyrosine residue is also a target of the negative regulator of gp130 signaling known as suppressor of cytokine signaling 3, or SOCS3, which is rapidly upregulated by IL-6 and leads to the inhibition of gp130 signaling (19, 22) . The four-membrane distal tyrosine residues of the cytoplasmic portion of gp130 are docking sites for signal transducer and activator of transcription 1 (STAT1) and 3 (STAT3), which become phosphorylated by JAK1, dimerize, and translocate to the nucleus, whereupon they act as transcription factors and lead to the transcription of IL-6 target genes, such as c-myc, bcl2, cyclin D1, MCP-1, Gremlin-1, several matrix metalloproteinases, and Notch (20, 23) . Transcription of STAT3 is negatively regulated by protein inhibitor of activated STAT (PIAS).
Intracellular IL-6 classic signaling and trans-signaling are qualitatively identical, though it has been shown that IL-6 trans-signaling leads to higher signal amplitudes because most IL-6R-expressing cells exhibit higher levels of gp130 than IL-6R (9) . Therefore, stimulation of such cells leads to fewer activated gp130 molecules than stimulation with the complex of IL-6 and sIL-6R, which can stimulate virtually all membrane-bound gp130 molecules (9) . Moreover, it was demonstrated that stimulation of IL-6R-expressing cells with IL-6 results in rapid internalization and degradation of IL-6, whereas the complex of IL-6 and sIL-6R is internalized ineffectively (24) . This results in longer signaling induced by the complex of IL-6 and sIL-6R than signaling induced by IL-6 alone (24). The higher signaling amplitude and the longer duration of signaling may result in qualitatively different IL-6 responses mediated by classic signaling and trans-signaling. For example, chemically induced liver cancer was recently shown to be dependent on IL-6 trans-signaling even though hepatocytes are one of the few cell types that express mIL-6R (25).
Interleukin-6 and the acute phase response
Stimulation of hepatocytes by IL-6 leads to initiation of the acute phase response and release of acute phase proteins, including C-reactive protein (CRP), serum amyloid A, haptoglobin, ferritin, and fibrinogen (26) . Elevated levels of acute phase proteins are the hallmark of inflammation and are routinely measured when monitoring inflammation in clinical practice (27) . IL-6 is the principal driver of the acute phase response in the pathogenesis of rheumatoid arthritis (RA), as evidenced by neutralization of IL-6 by the anti-IL-6R antibody tocilizumab, which led to the normalization of CRP (28) . Hepcidin is an acute phase protein that regulates iron metabolism; it reduces intestinal iron absorption and sequesters iron into macrophages (29) , which can lead to the development of anemia of chronic diseases (29) . In RA, the role of IL-6 signaling in the development of inflammatory anemia is supported by evidence showing that IL-6R blockade with tocilizumab reduces hepcidin and haptoglobin, as well as CRP, subsequently increasing hemoglobin levels (30) .
Innate immunity
Many innate immune cells and stromal cells produce and respond to IL-6 (17, 31) , highlighting the prominent role that this cytokine plays in the innate immune response and in its interaction with stromal cells (32) . Autocrine feedback can amplify inflammation (33) , and IL-6 is thought to be involved in the transition from acute to chronic inflammation. During acute inflammation, monocytes, macrophages, and endothelial cells produce IL-6, leading to the recruitment of neutrophils through activation of a subset of chemokines and adhesion molecules by endothelial cells, smooth muscle cells, and fibroblasts (31, 34) . IL-6 has also been shown to prolong neutrophil survival through regulatory effects on neutrophil apoptosis (35) . The shedding of mIL-6R from neutrophils during chronic inflammation allows stromal cells that do not express IL-6R to respond to IL-6, leading to the production of monocyte-specific chemoattractants (36, 37) and increasing monocyte influx (36, 38) .
Adaptive immunity
T and B cells are the main orchestrators of the adaptive immune response, which is central to the pathogenesis of many autoimmune diseases. Naive T and B cells are activated in the germinal centers of secondary lymphoid organs (39) . These activated effector T and B cells drive cellular-and humoral-mediated immunity to amplify inflammation and produce autoantibodies (39) . IL-6 has important roles in both T-and B-cell activation, as evidenced by the observation that IL-6-deficient animals are resistant to the development of antigen-induced arthritis (40) .
B cells
On engagement with an antigen through the B-cell receptor, B cells are activated, differentiate into plasma cells, and produce antibodies. IL-6 was originally identified as a T-cellderived soluble factor that induced the maturation of B cells into plasma cells (41) . In addition, IL-6 causes CD4 + and CD8 + T cells to differentiate into subsets that produce IL-21, which in turn stimulates B-cell maturation (42, 43) . IL-6-deficient animals have diminished antibody responses and are susceptible to infection (44) . A recent study has demonstrated a role for IL-6 in the induction of regulatory B cells (45) . IL-6 also allows the adaptive immune response to reciprocally impact the innate immune response because activated mature B cells and regulatory B cells produce IL-6, which then triggers innate immune cells and stromal cells to produce cytokines, chemokines, and other proinflammatory factors (32) . (46) showed that the presence of IL-6 inhibits TGF-β-induced differentiation of Treg cells. Furthermore, the presence of both IL-6 and TGF-β drives naive T cells to differentiate into Th17 cells (46) (47) (48) . IL-6 is also produced by Th17 cells, further promoting differentiation into Th17 cells (49) and the development of autoimmune diseases (50) . IL-6 and IL-17 released by Th17 cells induce fibroblasts to produce IL-6, further amplifying the immune reaction (51).
Endothelial cell function
IL-6 and IL-6R have been implicated in the pathogenesis of cardiovascular diseases. Human endothelial cells express gp130 but not IL-6R (9, 37, 52), whereas sIL-6R-mediated trans-signaling is known to increase the expression of adhesion molecules by endothelial cells and the binding of neutrophils, thereby causing vascular inflammation (37) . In collagen-induced arthritis-an animal model of RA-inflammatory arthritis is associated with impaired vascular contractile responses when stimulated by 5-hydroxytryptophan (53) . Blocking IL-6 trans-signaling with the soluble gp130Fc protein reverses vascular dysfunction to a normal state (54) .
Fibroblasts and fibrosis
IL-6 has been implicated in the pathogenesis of fibrotic diseases, including pulmonary (55) and hepatic (56) fibrosis and systemic sclerosis (SSc) (57) . Fibrosis is a common feature in chronic inflammatory diseases, whereas in fibrotic diseases, such as SSc, inflammatory infiltrates and cytokines are often found in affected organs (58) . Fibroblasts and macrophages, especially activated M2 macrophages, produce IL-6 and TGF-β, which are profibrotic cytokines (59, 60) . IL-6 transsignaling leads to increases in collagen 1 synthesis by STAT3 and SMAD3 activation and production of Gremlin-1, a bone morphogenetic protein antagonist (59) . Inhibiting Gremlin-1 reduced collagen synthesis. Serum amyloid A, an acute phase reactant produced by the liver, can induce dermal fibroblasts to produce IL-6 (61). IL-6-deficient mice were resistant to fibrosis in a peritoneal model of inflammation-mediated fibrosis; transfer of polarized Th1 cells reversed this effect, suggesting IL-6 caused fibrosis by shifting from chronic to acute inflammation through the induction of Th1 responses (62) . In hypertrophic scars, dermal fibroblasts express a high level of cell surface gp130, and IL-6 trans-signaling leads to the proliferation of fibroblasts and the excessive production of extracellular matrix, including procollagen and fibronectin (63) .
In patients with SSc, IL-6 levels are elevated in serum and in bronchoalveolar lavage fluid (64, 65) . Serum IL-6 levels correlate with skin scores (66) . Peripheral blood monocytes from patients with SSc produce more IL-6, either spontaneously or when stimulated (65, 67) . Elevated sIL-6R and sgp130 levels have been reported in 20 patients with localized scleroderma (68) . Fibroblasts from diseased skin sites of patients with SSc produce from 6-to 30-fold higher levels of IL-6 than fibroblasts from unaffected skin and healthy controls (69) .
Conclusion
IL-6 is produced by a number of cell types and exerts pleiotropic effects. In particular, IL-6 plays an important role in mediating innate and adaptive immune responses. Many innate immune cells-neutrophils and monocytes/macrophages-produce and respond to IL-6, which can result in the amplification of inflammation and a switch from an acute to a chronic inflammatory state. IL-6 is also involved in mediating the activation of T and B cells, which are the main drivers of adaptive immune responses and key cells in the pathogenesis of many autoimmune diseases. IL-6 has been implicated in the pathogenesis of fibrotic diseases, including SSc. Therefore, targeting IL-6 signaling may be a rational therapeutic target for the treatment of patients with these diseases.
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